Bio-Better Outcome On Biosimilars For FDA In Senate Funding Report
This article was originally published in The Pink Sheet Daily
Pressure on agency to finalize biosimilar guidances is still there, but unlike in the House, the Senate doesn't set the deadlines.
You may also be interested in...
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.